依达拉奉联合脑苷肌肽治疗重症颅脑损伤患者的疗效

目的 探讨依达拉奉联合脑苷肌肽治疗重症颅脑损伤患者的临床效果。方法 选择余江县人民医院2017年5月~2018年6月收诊的重症颅脑损伤患者50例，按照随机数字表法分为观察组与对照组，每组25例。对照组给予脑苷肌肽治疗，观察组则在对照组的基础上联合依达拉奉治疗。比较两组治疗前后丙二醛（MDA）、超氧化物歧化酶（SOD）、髓过氧化物酶（MPO）、谷胱甘肽过氧化物酶（GSH-Px）、脑钠肽（BNP）、神经元特异性烯醇化酶（NSE）、胶质原纤维酸性蛋白（GFAP）水平及临床疗效。结果 治疗后两组的MDA、MPO、NSE、GFAP水平均比治疗前降低，SOD、GSH-Px、BNP水平均比治疗前升高，且观察组各指标改善程度优于对照组，差异均有统计学意义（P＜0.05）；观察组的治疗总有效率（96.00%）高于对照组（76.00%），差异有统计学意义（P＜0.05）。结论 依达拉奉联合脑苷肌肽治疗重症颅脑损伤的效果确切，可有效抑制患者机体的氧化应激水平，促进神经功能尽早恢复。

Edaravone Combined with Cerebroside Carnosine in the Treatment of Patients with Severe Head Injury

Objective To investigate the clinical effects of edaravone combined with cerebroside carnosine in the treatment of patients with severe craniocerebral injury. Methods A total of 50 patients with severe craniocerebral injury who were admitted to Yujiang County People's Hospital from May 2017 to June 2018 were enrolled. The patients were divided into observation group and control group according to the random number table method, 25 cases in each group. The control group was treated with cerebroside carnosine, and the observation group was treated with edaravone on the basis of the control group. Comparison of malondialdehyde (MDA), superoxide dismutase (SOD), myeloperoxidase (MPO), glutathione peroxidase (GSH-Px), brain natriuretic peptide (BNP) before and after treatment , neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP) levels and clinical efficacy. Results The levels of MDA, MPO, NSE and GFAP in the two groups were lower than those before treatment. The levels of SOD, GSH-Px and BNP were higher than those before treatment, and the improvement of each index in the observation group was better than that of the control group,the difference was statistically significant (P<0.05). The total effective rate of treatment in the observation group (96.00%) was higher than that in the control group (76.00%),the difference was statistically significant (P<0.05). Conclusion Edaravone combined with cerebroside carnosine is effective in the treatment of severe craniocerebral injury, which can effectively inhibit the oxidative stress level of patients and promote the early recovery of neurological function.